<DOC>
	<DOCNO>NCT00657657</DOCNO>
	<brief_summary>In study , subject receive primary neonatal vaccination hepatitis B vaccine 0 , 1 , 2 , 12 month , 20 year ago 103860/272 primary study evaluate immunological memory hepatitis B vaccine via assessment response vaccine challenge dose .</brief_summary>
	<brief_title>Safety Immunogenicity Booster Dose GlaxoSmithKline ( GSK ) Biologicals ' Hepatitis B Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . A male female adult receive complete neonatal primary vaccination course hepatitis B vaccine ( Engerixâ„¢B ) , 103860/272 primary study approximately 20 year earlier . Documented level antiHBs antibody concentration &lt; 100 milliinternational unit per milliliter ( mIU/ml ) previous longterm timepoint serological result available subject . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . If subject female , must nonchildbearing potential childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion hepatitis B challenge dose . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior hepatitis B vaccine challenge dose . Planned administration/ administration vaccine foreseen study protocol period start 30 day hepatitis B vaccine challenge dose end 30 day . Subjects receive booster dose hepatitis B vaccine outside context study longterm timepoint document level antiHBs antibody concentration current challenge dose study visit . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . History allergic disease reaction likely exacerbate component vaccine . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . Acute disease time enrolment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Administration immunoglobulins and/or blood product within three month precede hepatitis B vaccine challenge dose plan administration study period . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Hepatitis</keyword>
	<keyword>vaccine</keyword>
</DOC>